Omadacycline was statistically non-inferior to moxifloxacin at the early clinical response, 72 to 120 hours after therapy was initiated.In May 2016, a phase Ib study of omadacycline in urinary tract infection was initiated.In August 2016, a second phase III study of omadacycline was initiated in patients with acute bacterial skin and skin structure infections, comparing the efficacy and safety of once-daily, oral omadacycline to that of twice-daily, oral linezolid. In July 2017, analysis of the data showed that all of the primary and secondary endpoints required for submission to the FDA and EMA were met. This was the third phase 3 registration study of omadacycline with favorable results. Discovery
Omadacycline was invented at Tufts University School of Medicine by a research team led by Mark L. Nelson with Mohamed Ismail while at Tufts and Kwasi Ohemeng and Laura Honeyman at Paratek Pharmaceuticals, Boston. The team applying their chemistry methods to the tetracycline scaffolds created over 3000 new derivatives, leading to the novel third-generation compounds omadacycline and sarecycline. References
External links
"Omadacycline". Drug Information Portal. U.S. National Library of Medicine. "Omadacycline tosylate". Drug Information Portal. U.S. National Library of Medicine. "Omadacycline Injection". MedlinePlus.
Assuming the pressure difference between the two sides of the barrier is much smaller than 
  
    
      
        
          P
          
            
              a
              v
              g
            
          
        
      
    
    {\displaystyle P_{\rm {avg}}}
  , the average absolute pressure in the system (i.e.